Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Inspira Technologies Oxy B.H.N. Ltd. (IINNW) provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings often include or reference press releases that describe product milestones, regulatory clearances, purchase orders, government-related discussions, and financing transactions.
Through its Form 6-K submissions, Inspira reports developments such as FDA 510(k) clearance and Israeli AMAR certification for the INSPIRA ART100 cardiopulmonary bypass system, government and institutional purchase orders for ART100 systems, and updates on the HYLA real-time blood sensor’s progress toward U.S. Food and Drug Administration submission. Other 6-K filings have covered matters like sales agreement amendments, private placements, and the activation of consulting firms to support business initiatives.
On this page, users can review how Inspira describes its INSPIRA ART platform, ART100 system, VORTX oxygenation technology, INSPIRA Cardi-ART device, and HYLA blood sensor within official filings. These documents outline the development status of each technology, including statements that certain products are still being designed and developed, have not been tested or used in humans, and are not yet approved by regulatory entities.
Stock Titan enhances access to these filings with tools that surface key sections and context from lengthy reports, helping readers quickly locate information on topics such as product regulatory status, capital raising activities, and material agreements. Real-time updates from EDGAR ensure that new Inspira Technologies filings, including future 6-Ks and other forms, appear here as they are submitted, alongside any disclosed information on warrants, purchase orders, or other corporate actions.
Inspira Technologies Oxy B.H.N. Ltd. files its annual Form 20-F, outlining its respiratory-focused medical device business and key risks. The company develops the INSPIRA ART blood-oxygenation platform, FDA-cleared INSPIRA ART100 cardiopulmonary bypass system, and HYLA real-time blood sensor targeting ICU and surgical settings.
The report highlights intense competition from large global medtech companies, dependence on distributors, supply-chain and cybersecurity risks, and heavy regulatory oversight in the U.S., EU and other markets. Inspira reports an accumulated deficit of about $80 million as of December 31, 2025, ongoing operating losses, limited cash resources, and substantial doubt about its ability to continue as a going concern.
The company notes it had approximately $3.1 million in cash, cash equivalents and deposits and working capital of about $1.6 million at December 31, 2025, which it expects will fund operations for roughly six months. Inspira also discloses Nasdaq minimum-bid-price deficiencies in March 2025 and February 2026, regaining compliance once but again facing a deadline of August 10, 2026 to restore its share price to at least $1.00 to avoid potential delisting.
Inspira Technologies Oxy B.H.N. Ltd. files its annual Form 20-F, outlining its respiratory-focused medical device business and key risks. The company develops the INSPIRA ART blood-oxygenation platform, FDA-cleared INSPIRA ART100 cardiopulmonary bypass system, and HYLA real-time blood sensor targeting ICU and surgical settings.
The report highlights intense competition from large global medtech companies, dependence on distributors, supply-chain and cybersecurity risks, and heavy regulatory oversight in the U.S., EU and other markets. Inspira reports an accumulated deficit of about $80 million as of December 31, 2025, ongoing operating losses, limited cash resources, and substantial doubt about its ability to continue as a going concern.
The company notes it had approximately $3.1 million in cash, cash equivalents and deposits and working capital of about $1.6 million at December 31, 2025, which it expects will fund operations for roughly six months. Inspira also discloses Nasdaq minimum-bid-price deficiencies in March 2025 and February 2026, regaining compliance once but again facing a deadline of August 10, 2026 to restore its share price to at least $1.00 to avoid potential delisting.
Inspira Technologies OXY B.H.N. Ltd executive Shabtay Abraham, the COO and VP of R&D, filed an initial ownership report showing his equity position in the company. He directly holds 1,332,713 ordinary shares, plus employee share options over 57,144 and 38,095 ordinary shares at an exercise price of $0.12 per share, expiring on April 20, 2030. His holdings also include multiple restricted stock unit grants that vest quarterly through early 2028 and additional RSUs that vest upon milestone achievements, reflecting a compensation package strongly tied to the company’s long-term performance.
Inspira Technologies OXY B.H.N. Ltd executive Shabtay Abraham, the COO and VP of R&D, filed an initial ownership report showing his equity position in the company. He directly holds 1,332,713 ordinary shares, plus employee share options over 57,144 and 38,095 ordinary shares at an exercise price of $0.12 per share, expiring on April 20, 2030. His holdings also include multiple restricted stock unit grants that vest quarterly through early 2028 and additional RSUs that vest upon milestone achievements, reflecting a compensation package strongly tied to the company’s long-term performance.
Inspira Technologies OXY B.H.N. Ltd director Tal Parnes filed an initial ownership report showing equity holdings in the company. Parnes directly holds 210,000 ordinary shares, plus share options covering 4,701 ordinary shares at an exercise price of $0.1200 per share, with expiration on April 20, 2030. The position also includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 100,001 restricted stock units vesting quarterly until February 1, 2028, indicating a mix of current ownership and future potential shares through options and RSUs.
Inspira Technologies OXY B.H.N. Ltd director Tal Parnes filed an initial ownership report showing equity holdings in the company. Parnes directly holds 210,000 ordinary shares, plus share options covering 4,701 ordinary shares at an exercise price of $0.1200 per share, with expiration on April 20, 2030. The position also includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 100,001 restricted stock units vesting quarterly until February 1, 2028, indicating a mix of current ownership and future potential shares through options and RSUs.
Inspira Technologies OXY B.H.N. Ltd director Matza Sivan filed an initial ownership report showing beneficial ownership of 30,000 ordinary shares. These include 9,999 restricted stock units that vest on October 21, 2026 and 20,001 restricted stock units that vest quarterly from January 21, 2027 until October 21, 2028.
Inspira Technologies OXY B.H.N. Ltd director Matza Sivan filed an initial ownership report showing beneficial ownership of 30,000 ordinary shares. These include 9,999 restricted stock units that vest on October 21, 2026 and 20,001 restricted stock units that vest quarterly from January 21, 2027 until October 21, 2028.
Inspira Technologies OXY B.H.N. Ltd director Amit Lior filed an initial ownership report showing beneficial ownership of 61,667 ordinary shares. This includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 20,001 restricted stock units vesting quarterly until February 1, 2028, all held directly.
Inspira Technologies OXY B.H.N. Ltd director Amit Lior filed an initial ownership report showing beneficial ownership of 61,667 ordinary shares. This includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 20,001 restricted stock units vesting quarterly until February 1, 2028, all held directly.
Inspira Technologies OXY B.H.N. Ltd Chief Technology Officer Daniella Yechezkely Hayon reported beneficial ownership of 830,000 ordinary shares as of the reported date. This is an initial ownership filing rather than a new trade.
The position includes restricted stock units: 36,667 RSUs vesting quarterly until February 1, 2027, 100,001 RSUs vesting quarterly until February 1, 2028, 100,000 RSUs vesting on July 1, 2026, 200,000 RSUs vesting quarterly beginning October 1, 2026 until July 1, 2028, and 100,000 RSUs that vest upon achieving specified milestones.
Inspira Technologies OXY B.H.N. Ltd Chief Technology Officer Daniella Yechezkely Hayon reported beneficial ownership of 830,000 ordinary shares as of the reported date. This is an initial ownership filing rather than a new trade.
The position includes restricted stock units: 36,667 RSUs vesting quarterly until February 1, 2027, 100,001 RSUs vesting quarterly until February 1, 2028, 100,000 RSUs vesting on July 1, 2026, 200,000 RSUs vesting quarterly beginning October 1, 2026 until July 1, 2028, and 100,000 RSUs that vest upon achieving specified milestones.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 showing Chief Executive Officer Ben-Noon Dagi Shahar as the beneficial owner of 2,927,239 ordinary shares held directly. This holding includes restricted stock units scheduled to vest quarterly through February 1, 2027 and February 1, 2028.
The filing also reports employee share options covering 57,159 ordinary shares with a converted exercise price of $0.12 per share. These options were granted on November 1, 2020, became fully vested as of January 1, 2021, and are exercisable until April 20, 2030.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 showing Chief Executive Officer Ben-Noon Dagi Shahar as the beneficial owner of 2,927,239 ordinary shares held directly. This holding includes restricted stock units scheduled to vest quarterly through February 1, 2027 and February 1, 2028.
The filing also reports employee share options covering 57,159 ordinary shares with a converted exercise price of $0.12 per share. These options were granted on November 1, 2020, became fully vested as of January 1, 2021, and are exercisable until April 20, 2030.
Inspira Technologies OXY B.H.N. Ltd reports a 5.2% beneficial ownership stake held by Dagi Ben-Noon. The reporting person beneficially owns 2,297,730 ordinary shares as of 12/31/2025, comprised of 326,739 shares, 1,913,832 RSUs vested or vesting within 60 days, and 57,159 options exercisable within 60 days. The percentage is based on 43,916,997 outstanding ordinary shares.
Inspira Technologies OXY B.H.N. Ltd reports a 5.2% beneficial ownership stake held by Dagi Ben-Noon. The reporting person beneficially owns 2,297,730 ordinary shares as of 12/31/2025, comprised of 326,739 shares, 1,913,832 RSUs vested or vesting within 60 days, and 57,159 options exercisable within 60 days. The percentage is based on 43,916,997 outstanding ordinary shares.
Inspira Technologies Oxy B.H.N. Ltd. reports two key updates. First, it amended its senior convertible debenture with Bio-View Ltd., extending the deadline to satisfy certain prerequisites from 45 to 75 days and revising the required $5,000,000 investment so it must come from investors introduced under a placement agreement with A.G.P/ Alliance Global Partners.
Second, Inspira received a Nasdaq notice that it is not meeting the minimum market value of publicly held shares requirement of $35,000,000. The company has 180 days, until August 18, 2026, for its market value of publicly held shares to reach at least $35,000,000 for 10 consecutive business days, or its securities may face delisting unless a Nasdaq hearings panel grants relief.
Inspira Technologies Oxy B.H.N. Ltd. reports two key updates. First, it amended its senior convertible debenture with Bio-View Ltd., extending the deadline to satisfy certain prerequisites from 45 to 75 days and revising the required $5,000,000 investment so it must come from investors introduced under a placement agreement with A.G.P/ Alliance Global Partners.
Second, Inspira received a Nasdaq notice that it is not meeting the minimum market value of publicly held shares requirement of $35,000,000. The company has 180 days, until August 18, 2026, for its market value of publicly held shares to reach at least $35,000,000 for 10 consecutive business days, or its securities may face delisting unless a Nasdaq hearings panel grants relief.
Inspira Technologies is expanding its U.S. presence by deploying its FDA-cleared INSPIRA™ ART100 system at a new premier New York academic medical center ranked among the state’s top 10 hospitals. The system is being integrated into the hospital’s clinical workflow for a structured commercial evaluation.
The evaluation aims to define clinical protocols and assess potential broader institutional adoption, adding to existing commercial activity at other leading U.S. healthcare facilities. Inspira positions the ART100 as a foundation for its next-generation ART500 awake-oxygenation system and is also advancing its HYLA™ continuous blood monitoring platform.
Inspira Technologies is expanding its U.S. presence by deploying its FDA-cleared INSPIRA™ ART100 system at a new premier New York academic medical center ranked among the state’s top 10 hospitals. The system is being integrated into the hospital’s clinical workflow for a structured commercial evaluation.
The evaluation aims to define clinical protocols and assess potential broader institutional adoption, adding to existing commercial activity at other leading U.S. healthcare facilities. Inspira positions the ART100 as a foundation for its next-generation ART500 awake-oxygenation system and is also advancing its HYLA™ continuous blood monitoring platform.